Objective: Most cancer patients become increasingly anxious toward the end of their life. The objective of this study was to identify predictors of increased opioid dosage in the last week of a terminal cancer patient's life. Methods: We retrospectively reviewed charts of patients who died in our palliative care unit. We assigned the patients to increased group or decreased group according to changes in oral morphine equivalent dosage in their last 7 days. Logistic regression analysis was used to identify predictors of increased oral morphine equivalent dosage. Results: We analyzed data of 158 patients (female: 43.7%, median age: 64 years). The median oral morphine equivalent dosages on Days 7 and 1 before death were 50 mg (interquartile range: 24 -122) and 61 mg (28 -129), respectively. Independent predictors of increased oral morphine equivalent dosage included dyspnea (odds ratio: 11.5, 95% confidence interval: 4.98 -28.83, P , 0.01), age ,65 years (odds ratio: 2.3, 95% confidence interval: 1.04 -5.26, P ¼ 0.04) and oral morphine equivalent dosage ,50 mg on Day 7 before death (odds ratio: 3.7, 95% confidence interval: 1.68-8.89, P , 0.01). The median oral morphine equivalent dosages on Days 7 and 1 before death were 48 mg (interquartile range: 20 -126) and 75 mg (36 -170) in patients with dyspnea, and 50 mg (25-120) and 57 mg (25-124) in patients with pain, respectively. Conclusions: Dyspnea, relative youth and oral morphine equivalent dosage ,50 mg on Day 7 before death were predictive of increased oral morphine equivalent dosage in the last 7 days. Our findings may help oncologists to more accurately inform patients about expected opioid requirements and thus relieve their end-of-life anxiety.
INTRODUCTION
Most cancer patients experience multiple symptoms, including pain and dyspnea, caused by tumor progression (1) . Dyspnea was severe and affected the both physical and psychological activities for advanced cancer patients (2) . Almost 50-70% of patients with advanced cancer experienced dyspnea in the last 6 weeks, and dyspnea gradually worsened with tumor progression (3, 4) . In the systematic review about cancer related dyspnea (5) showed subcutaneous morphine (6, 7) or subcutaneous morphine combined with midazolam (8) had immediately improved dyspnea in patients with dyspnea.
Cancer pain relief by morphine and other opioids has been set as a priority by the World Health Organization (WHO), and practical guidelines have been published (9) . However, there are several barriers to the adequate treatment of cancer pain. For instance, cancer pain has also been associated with psychosocial factors such as psychological distress, depression, anxiety and fear (10) . Moreover, the lack of exact information about pain can cause misinterpretation of the patient's state and further increase anxiety (11) . Functional magnetic resonance imaging suggested that pain can be modulated by anxiety (12) (13) (14) , possibly via the action of neurotransmitters (15) .
Patients in palliative care units (PCUs) and outpatient clinics become more anxious as pain becomes more severe near the end of life. Providing early information about expected escalation of morphine dosage to the patients and their families could help reduce the burden associated with anxiety. Previous studies have reported the amount of morphine in the last 24 h and the change of morphine dosage during the last 2 days before death (16) (17) (18) (19) (20) (21) (22) (23) . A study about change of symptom scores evaluated using Edmonton Symptom Assessment Scale showed that pain scores decreased but dyspnea scores increased in the last week of the cancer patients. So we need the detailed information to explain our patients about change of morphine dosage during the last week of their lives and to relieve patients' burden derived from unnecessary anxiety. The aim of this study was to show the change of morphine dosage and to identify predictors of increased opioid dosage in the last week of a terminal cancer patient's life. We herein revealed that (i) the increase of oral morphine equivalent (OME) in the last 7 days was frequently seen in patients with dyspnea, relative youth and small OME. (ii) The change of OME in patients with pain was small in the last 7 days.
PATIENTS AND METHODS
Patients who died in the PCU at the National Cancer Center Hospital East from October 2010 to September 2011 were eligible for this study. We excluded patients who had taken no opioids in the last 7 days before death, who died within 6 days from admission or who were being continuously administered with midazolam for status epilepticus.
Data were collected from electronic charts. Collected data included patients' characteristics; site of primary lesion; opioid dose at Days 7, 3 and 1 before death; major reason of change of morphine dose; use of sedation and medication of psychotropic drugs. The dosage of opioids combined with 'regular' and 'as required' medication was converted to OME following a standard ratio (24) . According to chart review, we divided the major reasons of change of morphine dosage into two categories: 'dyspnea' and 'pain'. When rescue-dose was administered, nurses were needed to identify sufferings and record them. Rescue-dose was not used for agitation. In this study, we focused on the reasons of change of the amount of opioids, because the reason of opioid administration during the last 7 days before death was ignored owing to obscure and imprecise information.
This study was performed according to the Declaration of Helsinki and was approved by the National Cancer Center Institutional Review Board.
STATISTICS
Patients were assigned to either of two groups according to changes in OME between Days 7 and 1 before death: the increase of OME group (OME increase ) and the equal or decrease of OME group (OME decrease ). Continuous variables were summarized as median (interquartile range [IQR] ). OME and length of stay were categorized based on their median value. Age was categorized as younger than 65 years, and 65 years or older. Categorical data were compared using the x 2 test. We conducted a stepwise logistic regression analysis to identify factors which were significantly associated with the increase of OME in the last 7 days. OME data at Days 7, 3 and 1 before death were compared with each other by Wilcoxon signed-rank test. Significance was set at P , 0.05.
RESULTS
Two hundred and forty-three patients were enrolled in this study ( Fig. 1 ). Of those, 208 patients (85.6%) took opioids. Reasons for exclusion were no use of opioids (35 patients), death within 6 days from admission (47 patients), and use of continuous midazolam for status epilepticus (3 patients). The remained 158 patients were considered for the analysis. Patient characteristics are summarized in Table 1 . Median age was 64 years (range: 30 -89 years). Sixty-nine patients (43.7%) were females. Sixty-two patients (39.2%) were admitted from their own home. The median OME at Days 7, 3 and 1 before death was 50 mg (IQR: 24-122 mg), 52 mg (27-120 mg) and 61 mg (28 -129 mg), respectively. The major reasons of change of OME in the last 7 days were dyspnea in 54 patients (34.2%) and pain in 104 patients (65.8%).
INDEPENDENT FACTORS FOR THE INCREASE OF OME IN THE LAST 7 DAYS
The distributions of categorical variables are summarized in Table 2 . Factors that were found to correlate with OME increase Figure 1 . Flowchart of patient selection process.
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were length of stay .18 days (54.4%, P ¼ 0.02) and admission from home (54.8%, P ¼ 0.04). In OME increase , 50 mg of OME at Day 7 before death was seen in 45 patients (54.9%), compared with .50 mg of OME in 26 patients (34.2%, P , 0.01). The major reason of change of OME in the last 7 days in OME increase was dyspnea (79.6%), compared with pain (26.9%, P , 0.01). Respiratory tract cancer was frequently observed in OME increase (60.0%), compared with other types of cancer (39.8%, P ¼ 0.03).
Stepwise logistic regression analysis identified the following independent predictive factors for an increase of OME: age 65 years (OR: 2.3, 95% CI: 1.04 -5.26, P ¼ 0.04); dyspnea (OR: 11.5, 95% CI: 4.98 -28.83, P , 0.01) and OME 50 mg at Day 7 before death (OR: 3.7, 95% CI: 1.68 -8.89, P , 0.01) ( Table 3) . Admission from home tended to be a predictive factor for an increase of OME (OR: 2.0, 95% CI: 0.93 -4.52, P ¼ 0.08).
VARIATION OF OME IN THE LAST 7 DAYS
The variation of OME in the last 7 days is summarized in Table 4 . The median dose of OME at Days 3 and 1 before death was significantly higher than that at Day 7 before death (P ¼ 0.03 and P , 0.01, respectively).
Next, we compared the changes of OME in the last 7 days for each predictive factor. The median dose of OME at Days 7, 3 and 1 before death was 48 mg (IQR: 20 -126 mg), 56 mg (28 -131 mg) and 75 mg (36 -170 mg) in the dyspnea group, and 50 mg (25 -120 mg), 51 mg (25 -119 mg) and 57 mg (25 -124 mg) in the pain group. The median dosage of OME at Days 3 and 1 before death was significantly higher than at Day 7 before death (P ¼ 0.02 and P , 0.01, respectively) in the dyspnea group. Additionally, the median dose of OME at Day 1 before death was higher than at Day 3 before death (P , 0.01). The median dosage of OME in the pain group slightly increased in the last 7 days.
The median dose of OME at Days 7, 3 and 1 before death was 60 mg (IQR: 30-180 mg), 72 mg (38-192 mg) and 78 mg (48 -194 mg) in patients aged 65 years, and 39 mg (15-70 mg), 40 mg (15 -75 mg) and 48 mg (15 -75 mg) in aged .65 years. The median dosage of OME at Day 1 before death significantly increased, compared with that at Day 7 before death in both age group (P ¼ 0.03 and P ¼ 0.03, respectively).
OPIOIDS TRANSITION IN THE LAST 7 DAYS
The transition of opioids in dyspnea or pain group were shown in Fig. 2 . In the pain group, 49.3 and 64.8% of patients were administered with morphine at 7 days and 1 day before death, respectively. In the dyspnea group, the proportion of morphine increased from 68.8% at 7 days before death to 88.7% at 1 day before death. Almost all patients with dyspnea were administered with morphine.
DISCUSSION
Cancer patients experience various burdens about diagnosis, treatment or adverse events of anti-cancer therapy, life expectancy, symptoms and psychosocial problems during the course of illness (25, 26) . The lack of information easily evokes anxiety and distress for patients, and it occasionally results in onset of anxiety-induced hyperalgesia (27) . Therefore, the exact information was needed to explain to patients. In this study, we identified the dyspnea and the young ,65 as predictors of increased opioid dosage in the last 7 days of a terminal cancer patient's life. Additionally, we revealed that the 
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Predictors of opioid increase in terminal cancer increase of opioid dosage in patients with pain was little. It meant pain did not so much worsen in the last 7 days in terminally ill patients. Cancer pain is one of the most important symptoms in advanced cancer patients. Opioids including morphine are strongly recommended by WHO guidelines. About 14 -83% of patients with terminal cancer take opioids (28) . Additionally, dyspnea was also severe symptoms for patients. Almost 50-70% of patients with advanced cancer experienced dyspnea in the last 6 weeks, and dyspnea gradually worsens with tumor progression (3, 4) . Poor performance status correlates with the presence of dyspnea (3, 4) . Morphine alleviates dyspnea via a decrease in the respiratory rate and effort (5 -7,29) . The present study revealed dyspnea, but not pain, as a predicting factor for escalation of morphine dosage. This is in agreement with previous studies that patients with lung cancer frequently need to increase their dose of morphine (30) . In the study about patients with advanced lung cancer, dyspnea interfered with both physical and psychological activity in patients with good performance status (2) . In another study revealed that many causes such as hypoxia, anemia and bronchospasm exist in advanced cancer patients with dyspnea (31) . The study also suggested severe weakness of respiratory muscle contributed to dyspnea. Muscle weakness might be derived from malnutrition or cachexia. Consequently, Dyspnea might cause more severe burden than pain in terminal cancer patients. Table 2 . Relationship between patient characteristics and increase of OME in the last 7 days before death
Cutoff
Total Increase of OME Decrease of OME P value 
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Our results suggest that oncologists, palliative care physicians and nurses have to carefully watch the change of patients' symptoms, to adequately alleviate the suffering of dyspnea by the increase of morphine, the use of midazolam or oxygen, and the psychological support including breath control or coping strategies. It is well known that aged cancer patients need lower doses of opioids than young cancer patients (32) , because the function of metabolism or secretion becomes gradually impaired with aging. Further study about pharmacodynamics in patients with terminally ill patients is needed for adequate medication. Additionally, pharmacogenetic study may help us to explain the dosage of opioids or frequency of adverse effect (33) . Recently, epigenetic modifications have been correlated with the onset of pain (34) . Further basic research including molecular mechanism, pharmacodynamics and pharmacogenomics will contribute to the development of individualized symptom management. The concept of total pain might also explain the reason why the young patients frequently need higher opioid dose. Total pain consists of physical, psychosocial and spiritual pain (9) . These factors could cause pain by only themselves, however, these factors complicatedly combined with each other. It is well known that the young cancer patients have many problems in their course of illness. Therefore, psychosocial and spiritual pain might greatly attribute to the worse of suffering in the young patients in the present study. Chronic musculoskeletal pain had still been considered as multidisciplinary disease including biological, psychological and social factors (35) . Psychological treatment is needed to be integrated into physical therapy and medication management (36) . In the treatment of the terminally ill patients, oncologists, palliative care physicians and medical staffs carefully approach to their psychological and social factors.
The present study showed that almost 90% of patients at Day 7 before death took opioids and the median value of OME was 50 mg. Our data corresponded well with a previous report by Morita et al. (37) and also indicated that the adequate dosage of opioids for relief of symptoms has already been administered in PCU. The dosages of opioids in the study by us and Morita et al. were still lower than the dosages in European countries. This difference has still been unresolved question. Therefore, detailed investigation about ethnic diversity in metabolism or secretion of opioids in the point of pharmacodynamics, and in threshold of suffering are needed.
The present study has limitations due to following reasons: (i) its retrospective design in a single center, (ii) a lack of information about the presence of lung metastasis, lymphangitis and pleural effusion, liver or renal function, which data were not routinely or correctly evaluated in our PCU, (iii) a lack of evaluation of the level of consciousness of the patients and Figure 2 . Opioids transition in the last 7 days. The use of morphine gradually increased in both groups. In the dyspnea group, almost all patients were administered with morphine a day before death. 
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Predictors of opioid increase in terminal cancer (iv) no evaluation about physical activity at 7 days before death.
CONCLUSION
The increase of OME in the last 7 days was frequently seen in patients with dyspnea, relative youth and small OME. The change of OME in patients with pain was small in the last 7 days. Our findings might help oncologists, palliative care physician and nurse to explain the exact information for their patients, to adequately increase OME for the patients with dyspnea, and to relieve the patients from the wasted anxiety for pain in their last days.
